Rhythm Pharmaceuticals (RYTM) stock has been in focus after a cluster of catalysts, including U.S. and European approvals for IMCIVREE in acquired hypothalamic obesity, as well as first quarter revenue of US$60.11 million alongside a net loss of US$55.64 million.

The recent approvals and data updates appear to be feeding into Rhythm Pharmaceuticals’ share price performance, with the stock at US$94.17 and a 7 day share price return of 10.04%. This follows a period where the year to date share price return is down 10.32%, while the 1 year total shareholder return of 59.70% and 3 year total shareholder return of more than 4x suggest longer term momentum has been strong.

If you are looking beyond Rhythm Pharmaceuticals and these recent approvals, this could be a good time to check out other rare disease and specialty biopharma opportunities through our healthcare focused screen for 34 healthcare AI stocks

With the stock up strongly over the past year and trading at US$94.17, alongside an indicated intrinsic discount and sizeable gap to analyst targets, you have to ask, is there still a buying opportunity here or has the market already priced in future growth?

Most Popular Narrative: 31.6% Undervalued

Rhythm Pharmaceuticals' most widely followed narrative points to a fair value of $137.67 versus the last close of $94.17, framing a sizeable valuation gap that hinges on how investors view future approvals, margins and earnings power.

Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader Willi syndrome, alongside expansion into younger age groups, are expected to materially grow Rhythm's commercial opportunity and topline over the next several years. Extension of intellectual property protection to 2034 for the lead asset and to 2040+ for next generation compounds, along with orphan drug exclusivity incentives in the U.S. and EU, create a multi year window of strong pricing power and high net margins, protecting earnings from generic/biosimilar erosion.

Want to see what kind of revenue ramp and margin shift would need to support that fair value? The narrative leans on aggressive topline growth, a sharp turn into profitability and a rich future earnings multiple usually reserved for market leaders in faster growing sectors.

Result: Fair Value of $137.67 (UNDERVALUED)

However, this hinges on Rhythm turning heavy losses around while still relying on IMCIVREE. Any regulatory setback or slower uptake could quickly challenge that upside story.

Another View: What The Sales Multiple Is Telling You

The first valuation leans heavily on analyst forecasts and a discounted cash flow view. By contrast, the current P/S ratio of 29.7x is far higher than the US Biotechs industry at 10.3x, peers at 7.7x, and a fair ratio of 17x. This signals that a lot has already been priced in.

For you, that raises a simple question: does the high sales multiple reflect justified optimism, or does it leave less room if expectations on growth or profitability are revised?

Next Steps

With sentiment this mixed, it helps to move quickly and test the assumptions yourself using the latest data. To see what investors are currently optimistic about, review the 3 key rewards.

Looking for more investment ideas?

If Rhythm Pharmaceuticals has your attention, do not stop here. The same tools can help you spot other opportunities that might fit your style even better.

• Target reliable income by reviewing 12 dividend fortresses that could help anchor your portfolio with regular payouts.
• Hunt for quality at a discount by scanning 49 high quality undervalued stocks before other investors catch on.
• Strengthen your downside protection by focusing on 71 resilient stocks with low risk scores so potential setbacks do not catch you off guard.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.